

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1460, on December 2, 2003. TECH CENTER 1800, ED

Tami M. Procopio

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Asim DASGUPTA et al.

Serial No.:

09/836,073

Filing Date:

April 16, 2001

For:

METHODS TO INHIBIT VIRAL

REPLICATION

Examiner: Sean McGarry

Group Art Unit: 1635

INFORMATION DISCLOSURE **STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

12/10/2003 MGEBREM1 00000040 031952 09836073

02 FC:1806

180.00 DA

	11113 111.	ionnation Discressive Statement is satirated.
	With	the application; accordingly, no fee or separate requirements are required.
	Befor	e the mailing of a first Office Action after the filing of a Request for Continued
	Exam	ination under § 1.114.
	Withi	n three months of the application filing date or before mailing of a first Office
	Actio	n on the merits; accordingly, no fee or separate requirements are required.
\boxtimes	After	receipt of a first Office Action on the merits but before mailing of a final Office
	Actio	n or Notice of Allowance.
		A fee is required. A check in the amount of is enclosed.
	\boxtimes	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached
		to this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee
		is believed to be due.
	After	mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue	fee.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the
		amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal
		form (PTO/SB/17 is attached to this submission in duplicate.)

This Information Disclosure Statement is submitted:

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 220002054822. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: December 2, 2003

Respectfully submitted,

Kate H. Murashige

Reg. No. 29,959

Morrison & Foerster LLP

3811 Valley Centre Drive, Suite 500 San Diego, California 92130-2332

Telephone: (858) 720-5117 Facsimile: (858) 720-5125

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)

			1 10/30/00 (2-92	· <i>)</i>
			Sheet 1 of	2
Docket Number 22000205	4822	Application Nu	mber 09/836,073	7
Applicant	Asim DAS	GUPTA et al.	7/	
Filing Date April 16, 2001		Group Art Unit	1636 CC OF	
Mailing Date December 2,	2003		CENT	71
			EA 16	003
DOCUMENTS				130
Name	Class	Subclose	Eiling Date If	

RADEMA	17.00		U.S. PATENT DOCUMENTS		
aminer	Ref.	Date	Document No.	Name	

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Trans YES	lation NO
Ì		1.	04/1996	WO 96/11211	WIPO				

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	2.	Agol, Adv. Virus Res. (1991) 40:103-180
i)	3.	Agrawal, TIBTACH Vol. 14:376-387
	4.	Bandopadhyay et al., J. Virol. (1992) 66:6249-6256
	5.	Belsham et al., J. Virol. (1990) 64:5389-5395
······································	6.	Borman et al., Gen. Virol. (1993) 74:1775-1788
***	7.	Borman et al., Virology (1992) 188:685-696
	8.	Borovjagin et al., Nucleic Acids Res. (1991) 19:4999-5005
	9.	Brown and Ehrenfeld., Virology (1979) 97:396-405
	10.	Chambers et al., J Biol Chem (1988) 263(34):18043-18061
	11.	Chang et al., J. Virol. (1993) 67:6716-6725
	12.	Chang et al., J. Virol. (1994) 68(11):7008-7020
	13.	Coward, J Cell. Biochem. (1991) Suppl. 15E, abstract M311, p.82
	14.	Coward and Dasgupta, J. Virol. (1992) 66:286-295
	15.	Das et al., J. Virol. (1994) 68(11):7200-7211
	16.	Del Angel et al., Proc. Natl. Acad. Sci. USA (1989) 86:8299-8303

EXAMINER: (examiner) DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92) sd- 166572

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

IN AN (Use seven) 17. Dor 18. Geb 19. Gla. 20. Hel 21. Jack 22. Jang 23. Kita 24. Koz	DISCLOSURE CITATION APPLICATION ral sheets if necessary) mer et al., J. Virol. (1984) 50:507-5 phard and Ehrenfeld, J. Virol. (1995) ss et al., Virology (1993) 193:842- len et al., Proc. Natl. Acad. Sci. US kson et al., Trends Biochem. Sci. (1995)	Filing Date April 16, 2001 Mailing Date December 2, 2003 514 2) 66:3101-3109	Group Art Unit 1635 CECHOENTER 1600/290
IN AN (Use seven) 17. Dor 18. Geb 19. Gla. 20. Hel 21. Jack 22. Jang 23. Kita 24. Koz	APPLICATION ral sheets if necessary) mer et al., J. Virol. (1984) 50:507-5 phard and Ehrenfeld, J. Virol. (1995) ss et al., Virology (1993) 193:842-6 len et al., Proc. Natl. Acad. Sci. Useson et al., Trends Biochem. Sci. (1995)	Filing Date April 16, 2001 Mailing Date December 2, 2003 514 2) 66:3101-3109	Group Art Unit 1635
17. Dor 18. Geb 19. Gla 20. Hel 21. Jack 22. Jang 23. Kita 24. Koz	rner et al., J. Virol. (1984) 50:507-5 phard and Ehrenfeld, J. Virol. (1995) ss et al., Virology (1993) 193:842-6 len et al., Proc. Natl. Acad. Sci. US kson et al., Trends Biochem. Sci. (Mailing Date December 2, 2003 514 2) 66:3101-3109 852	
17. Dor 18. Geb 19. Gla 20. Hel 21. Jack 22. Jang 23. Kita 24. Koz	ohard and Ehrenfeld, J. Virol. (1990) ss et al., Virology (1993) 193:842- len et al., Proc. Natl. Acad. Sci. US kson et al., Trends Biochem. Sci. (514 2) 66:3101-3109 -852	PECE/V
18. Geb 19. Gla 20. Hel 21. Jack 22. Jang 23. Kita 24. Koz	ohard and Ehrenfeld, J. Virol. (1990) ss et al., Virology (1993) 193:842- len et al., Proc. Natl. Acad. Sci. US kson et al., Trends Biochem. Sci. (2) 66:3101-3109 852	PECEIV
18. Geb 19. Gla 20. Hel 21. Jack 22. Jang 23. Kita 24. Koz	ohard and Ehrenfeld, J. Virol. (1990) ss et al., Virology (1993) 193:842- len et al., Proc. Natl. Acad. Sci. US kson et al., Trends Biochem. Sci. (2) 66:3101-3109 852	DEC EIV
19. Gla. 20. Hel 21. Jack 22. Jang 23. Kita 24. Koz	ss et al., Virology (1993) 193:842- len et al., Proc. Natl. Acad. Sci. US kson et al., Trends Biochem. Sci. (852	DEC TELL
20. Hel 21. Jack 22. Jang 23. Kita 24. Koz	len et al., Proc. Natl. Acad. Sci. US kson et al., Trends Biochem. Sci. (150, 7
21. Jack 22. Jang 23. Kita 24. Koz	kson et al., Trends Biochem. Sci. (SA (1993) 90·76/2_76/6	
22. Jang 23. Kita 24. Koz		3A (1993) 90.7042-7040	ENTED COO3
23. Kita 24. Koz		1990) 15:477-483	1600/20
24. Koz	g and Wimmer, Genes Dev. (1990)	4:1560-1572	1500
	amura et al., Nature (1981) 291:54	7-553	
25 I 112	zak, Microbiol. Rev. (1983) 47:1-4	5	
23. Luz	and Beck, FEBS Letters (1990) 2	69:311-314	
26. Luz	et al., Virology (1991) 65:6486-6	494	
27. Mad	cejak and Sarnow, Nature (1991) 3	53:90-94	
28. Mee	erovitch et al., Genes & Dev. (1989	9) 3:1026-1034	
29. Med	erovitch et al., J. Virol. (1993) 67:3	3798-3807	
30. Naj	ita and Sarnow, Proc. Natl. Acad.	Sci. USA (1990) 87:5846-5850)
31. Oh	et al., Genes Dev. (1992) 6:1643-1	653	
32. Pell	etier et al., J. Virol. (1988) 62:448	6-4492	
33. Pell	etier and Sonenberg, Nature (1988	3) 334:320-325	
34. Pest	tova et al., J. Virol. (1991) 65:6194	4-6204	
35. Pilij	penko et al., Cell (1992) 68:119-13	31	
36. Rac	aniello and Baltimore, Proc. Natl.	Acad. Sci. USA (1981) 78:488	7-4891
37. Skir	nner et al., J. Mol. Biol. (1989) 207	7:379-392	
38. Stul	l and Szoka, Pharmaceutical Research	arch 12(4):465-483	
39. Tsu	kiyama-Kohara et al., J. Virol. (19	92) 66:1476-1483	
40. Inte	rnational Search Report based on l	International Application No. F	CT/US99/11281